- Conditions
- Pancreatic Neoplasms, Rectal Neoplasms
- Interventions
- Blue light, Amber light, Ambient White Light
- Device · Other
- Lead sponsor
- Matthew Neal MD
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 26,232
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Islet Cell, Carcinoma, Pancreas
- Interventions
- sunitinib malate, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more
- Conditions
- Neuroblastoma
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 6 Months to 99 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1999
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Intracranial Meningioma
- Interventions
- Everolimus, Bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Louisville, Kentucky • Omaha, Nebraska + 4 more
- Conditions
- Indolent Lymphoma
- Interventions
- Copanlisib, Nivolumab, Rituximab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 1 more
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • San Francisco, California • Stanford, California + 9 more
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Melphalan
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Colorectal Cancer
- Interventions
- Text Messaging
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Urothelial Carcinoma
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Arjun Balar, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Minneapolis, Minnesota + 4 more
- Conditions
- Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Transfusion Dependent Cytopenias
- Interventions
- Home Blood Transfusion
- Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Biological · Other
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 45
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Interventions
- Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Hysterectomy, Laboratory Biomarker Analysis, Lymph Node Mapping, Sentinel Lymph Node Biopsy
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ixabepilone, lapatinib ditosylate
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pemetrexed, Bevacizumab, Carboplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 24 more
- Conditions
- Triple Negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- Pembrolizumab, PVX-410
- Drug · Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Cancer
- Interventions
- Sterile Humidification Device
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hematologic Malignancies
- Interventions
- Clofarabine, Stem Cell Transplantation, Hematopoietic, OKT3, Thiotepa, Melphalan, Mycophenolate mofetil, Rituximab, G-CSF
- Drug · Procedure · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Melanoma
- Interventions
- Ensartinib, ALKATI by Customized Nanostring Assay
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Middletown, New Jersey • Montvale, New Jersey • East White Plains, New York + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan, Velcade, Thalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Ovarian Cancer
- Interventions
- ON 01910.Na
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
- Interventions
- Efineptakin alfa
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Bethesda, Maryland • Seattle, Washington